AMPH PE Ratio & Valuation,Is AMPH Overvalued

AMPH Relative Valuation

AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMPH is overvalued; if below, it's undervalued.

Historical Valuation

Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.32 is considered Undervalued compared with the five-year average of 14.30. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 32.72 to 57.88 according to relative valuation methord. Compared to the current price of 25.27 USD , Amphastar Pharmaceuticals Inc is Undervalued By 22.77%.

Relative Value

Fair Zone

32.72-57.88

Current Price：25.27

22.77%

Undervalued

7.32

5.81

EV/EBITDA

Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBITDA of 5.81. The 5-year average EV/EBITDA is 8.55. The thresholds are as follows: Strongly Undervalued below 4.98, Undervalued between 4.98 and 6.76, Fairly Valued between 10.33 and 6.76, Overvalued between 10.33 and 12.11, and Strongly Overvalued above 12.11. The current Forward EV/EBITDA of 5.81 falls within the Undervalued range.

7.45

EV/EBIT

Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBIT of 7.45. The 5-year average EV/EBIT is 10.50. The thresholds are as follows: Strongly Undervalued below 5.49, Undervalued between 5.49 and 7.99, Fairly Valued between 13.00 and 7.99, Overvalued between 13.00 and 15.51, and Strongly Overvalued above 15.51. The current Forward EV/EBIT of 7.45 falls within the Undervalued range.

1.61

Amphastar Pharmaceuticals Inc. (AMPH) has a current PS of 1.61. The 5-year average PS is 2.56. The thresholds are as follows: Strongly Undervalued below 1.29, Undervalued between 1.29 and 1.92, Fairly Valued between 3.20 and 1.92, Overvalued between 3.20 and 3.83, and Strongly Overvalued above 3.83. The current Forward PS of 1.61 falls within the Undervalued range.

5.50

P/OCF

Amphastar Pharmaceuticals Inc. (AMPH) has a current P/OCF of 5.50. The 5-year average P/OCF is 9.79. The thresholds are as follows: Strongly Undervalued below 4.72, Undervalued between 4.72 and 7.25, Fairly Valued between 12.32 and 7.25, Overvalued between 12.32 and 14.86, and Strongly Overvalued above 14.86. The current Forward P/OCF of 5.50 falls within the Undervalued range.

7.42

P/FCF

Amphastar Pharmaceuticals Inc. (AMPH) has a current P/FCF of 7.42. The 5-year average P/FCF is 9.07. The thresholds are as follows: Strongly Undervalued below -104.07, Undervalued between -104.07 and -47.50, Fairly Valued between 65.64 and -47.50, Overvalued between 65.64 and 122.20, and Strongly Overvalued above 122.20. The current Forward P/FCF of 7.42 falls within the Historic Trend Line -Fairly Valued range.

Amphastar Pharmaceuticals Inc (AMPH) has a current Price-to-Book (P/B) ratio of 1.51. Compared to its 3-year average P/B ratio of 2.98 , the current P/B ratio is approximately -49.45% higher. Relative to its 5-year average P/B ratio of 2.86, the current P/B ratio is about -47.33% higher. Amphastar Pharmaceuticals Inc (AMPH) has a Forward Free Cash Flow (FCF) yield of approximately 9.75%. Compared to its 3-year average FCF yield of 7.38%, the current FCF yield is approximately 32.08% lower. Relative to its 5-year average FCF yield of 6.37% , the current FCF yield is about 53.10% lower.

1.51

P/B

Median3y

2.98

Median5y

2.86

9.75

FCF Yield

Median3y

7.38

Median5y

6.37

Competitors Valuation Multiple

The average P/S ratio for AMPH's competitors is 391.14, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH) exhibits a P/S ratio of 1.61, which is -99.59% above the industry average. Given its robust revenue growth of 0.33%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AMPH decreased by 31.94% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 8.90 to 11.13.

The secondary factor is the Revenue Growth, contributed 0.33%to the performance.

Overall, the performance of AMPH in the past 1 year is driven by P/E Change. Which is more unsustainable.

0.33%

191.21M → 191.84M

Revenue Growth

-57.24%

21.14 → 9.04

Margin Expansion

24.97%

8.90 → 11.13

P/E Change

-31.94%

37.13 → 25.27

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Amphastar Pharmaceuticals Inc (AMPH) currently overvalued or undervalued?

What is Amphastar Pharmaceuticals Inc (AMPH) fair value?

AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 32.72 to 57.88 according to relative valuation methord.

How does AMPH's valuation metrics compare to the industry average?

What is the current P/B ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 15 2025?

As of Dec 15 2025, Amphastar Pharmaceuticals Inc (AMPH) has a P/B ratio of 1.51. This indicates that the market values AMPH at 1.51 times its book value.

What is the current FCF Yield for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 15 2025?

As of Dec 15 2025, Amphastar Pharmaceuticals Inc (AMPH) has a FCF Yield of 9.75%. This means that for every dollar of Amphastar Pharmaceuticals Inc’s market capitalization, the company generates 9.75 cents in free cash flow.

What is the current Forward P/E ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 15 2025?

As of Dec 15 2025, Amphastar Pharmaceuticals Inc (AMPH) has a Forward P/E ratio of 7.32. This means the market is willing to pay $7.32 for every dollar of Amphastar Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Amphastar Pharmaceuticals Inc (AMPH) as of Dec 15 2025?

As of Dec 15 2025, Amphastar Pharmaceuticals Inc (AMPH) has a Forward P/S ratio of 1.61. This means the market is valuing AMPH at $1.61 for every dollar of expected revenue over the next 12 months.

AMPH Valuation